The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Biomarin Pharmaceutical Inc. is $16.92B. A total of 1.61 million shares were traded on the day, compared to an average of 1.69M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, BMRN has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 52 BUYs and 37 SELLs from insiders. Insiders purchased 665,872 shares during that period but sold 378,385.
In the most recent transaction, BIENAIME JEAN JACQUES sold 10,000 shares of BMRN for 96.38 per share on Jan 10. After the transaction, the Director now owns 425,162 company shares. In a previous transaction on Jan 09, BIENAIME JEAN JACQUES sold 10,000 shares at 98.19 per share. BMRN shares that Director owns now total 425,162.
Among the insiders who sold shares, BIENAIME JEAN JACQUES disposed of 10,000 shares on Dec 21 at a per-share price of $93.99. This resulted in the Director holding 425,112 shares of BMRN after the transaction. In another insider transaction, Davis George Eric sold 13,764 shares at $95.30 per share on Dec 13. Company shares held by the EVP, Chief Legal Officer now total 55,710.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for BMRN in the last 3 months, the mean price target is $110.83 with high estimates of $150.00 and low estimates of $78.00. In terms of 52-week highs and lows, BMRN has a high of $112.98 and a low of $76.02.
As of this writing, BMRN has an earnings estimate of $0.23 per share for the current quarter. EPS was calculated based on a consensus of 18 estimates, with a high estimate of $0.39 per share and a lower estimate of $0.11. The company reported an EPS of $0.29 in the last quarter, which was 26.10% higher than expectations of $0.23.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BMRN’s latest balance sheet shows that the firm has $1.01B in Cash & Short Term Investments as of fiscal 2021. There were $1.09B in debt and $546.50M in liabilities at the time. Its Book Value Per Share was $26.00, while its Total Shareholder’s Equity was $4.27B.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMRN is Buy with a score of 4.36.